- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00822250
Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis
March 26, 2026 updated by: Centre Hospitalier Universitaire de Nice
The purpose of this study is to determine the molecular mechanism of this disease and to research the relationship between cystinosis and skin phenotype.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nice, France, 06000
- department of dermatology, Nice University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 15 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- cystinosis
- known CTNS mutation
Exclusion Criteria:
- patient with corticotherapy treatment
- patient with immunosuppressant treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: 1
cutting hair, skin phenotype description
|
cutting hair, skin description, skin biopsy for only 4 patients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
to determine molecular mechanism of the disease
Time Frame: at time= 0
|
at time= 0
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
to research relationship between skin phenotype and cystinosis
Time Frame: at time =0
|
at time =0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
January 13, 2009
First Submitted That Met QC Criteria
January 13, 2009
First Posted (Estimated)
January 14, 2009
Study Record Updates
Last Update Posted (Actual)
March 31, 2026
Last Update Submitted That Met QC Criteria
March 26, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-PP-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystinosis
-
University of California, San DiegoRaptor Pharmaceuticals Corp.CompletedCystinosis | Nephropathic CystinosisUnited States
-
Chiesi SA/NVEnrolling by invitationNephropathic CystinosisBelgium
-
Cystinose StiftungLabor Becker & Kollegen, Munich, Germany; Screening Labor Hannover; Genetikum... and other collaboratorsCompletedSpinal Muscular Atrophy | Cystinosis | Cystinosis, NephropathicGermany
-
Institut Jean-GodinotUniversité de Reims Champagne-ArdenneNot yet recruiting
-
Eloxx Pharmaceuticals, Inc.TerminatedGenetic Disease | Cystinosis | Nonsense MutationCanada
-
Stanford UniversityCompleted
-
Stephanie CherquiNovartis Pharmaceuticals; California Institute for Regenerative Medicine (CIRM) and other collaboratorsEnrolling by invitationCystinosisUnited States
-
Recordati Rare DiseasesCompletedCystinosisBelgium, France, United Kingdom, Germany, Italy
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
National Eye Institute (NEI)CompletedCystinosisUnited States
Clinical Trials on analysis of pigmentation
-
Emory UniversityWithdrawn
-
Assiut UniversityCompleted
-
Centre Hospitalier Universitaire DijonRecruiting
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Ain Shams UniversityCompleted
-
University of ParmaITI International Team for Implantology, SwitzerlandCompletedInflammation | Periodontitis | Peri-ImplantitisItaly
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UnknownBreast Cancer | brca1 Mutation Carrier | brca2 Mutation CarrierUnited States
-
Cancer Research UKUnknown
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Completed
-
IRCCS Policlinico S. DonatoRecruiting